Wanbury Ltd.

NSE: WANBURY BSE: 524212 SECTOR: Pharmaceuticals & Drugs  4792   11   1

76.80
-0.40 (-0.52%)
NSE: 22 Oct 03:40 PM

Price Summary

Today's High

₹ 78.65

Today's Low

₹ 75.2

52 Week High

₹ 114

52 Week Low

₹ 33

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

250.79 Cr.

Enterprise Value

397.77 Cr.

No. of Shares

3.27 Cr.

P/E

0

P/B

0

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  -25.1

CASH

16.66 Cr.

DEBT

163.63 Cr.

Promoter Holding

39.9 %

EPS (TTM)

₹  -0.71

Sales Growth

-6.11%

ROE

0 %

ROCE

204.91%

Profit Growth

359.41 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-6.11%
3 Year-5.38%
5 Year8.01%

Profit Growth

1 Year359.41%
3 Year1.3%
5 Year82.23%

ROE%

1 Year0%
3 Year0%
5 Year0%

ROCE %

1 Year204.91%
3 Year76.79%
5 Year60.61%

Debt/Equity

-1.3862

Price to Cash Flow

5.68

Interest Cover Ratio

2.96743300264369

CFO/PAT (5 Yr. Avg.)

3.08117091589812

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2021 39.9 76.76
Jun 2021 39.9 76.76
Mar 2021 52.09 76.76
Dec 2020 52.09 76.76
Sep 2020 52.09 76.76
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 76.7885103465252% over the past 3 years.
  • The company has an efficient Cash Conversion Cycle of -81.292509155462 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 38.7165851942678.

 Limitations

  • The company has shown a poor profit growth of 1.29752243772721% for the Past 3 years.
  • The company has shown a poor revenue growth of -5.3831868586248% for the Past 3 years.
  • Company has a poor ROE of 0% over the past 3 years.
  • Promoter pledging has increased from 39.9% to 76.76% in 1 quarter.
  • Company has contingent liabilities of 1012.0915 Cr.
  • The company has a low EBITDA margin of -1.62066882999457% over the past 5 years.
  • The company has negative book value.
  • Promoter stake has been decreased from 52.09% to 39.9%.
  • Promoter pledging is high as 76.76%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Net Sales 67.16 95.21 109.7 120.45 127.86
Total Expenditure 70.12 86.23 95.94 122.22 121.31
Operating Profit -2.96 8.98 13.76 -1.77 6.55
Other Income 0.26 0.13 0.8 1.21 0.31
Interest 6.05 5.02 6.21 5.79 5.02
Depreciation 2.37 2.4 2.39 2.59 2.64
Exceptional Items 0 0 0 0 0
Profit Before Tax -11.12 1.68 5.96 -8.93 -0.81
Tax 0.04 0.08 0.05 0.03 0.06
Profit After Tax -11.16 1.6 5.91 -8.96 -0.86
Adjusted EPS (Rs) -4.47 0.64 2.36 -3.58 -0.26

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 423.26 433.81 371.1 391.37 367.45
Total Expenditure 390.78 415.28 439.01 378.01 389.07
Operating Profit 32.48 18.53 -67.9 13.37 -21.62
Other Income 1.41 89.69 76.7 11.5 46.2
Interest 31.87 35.51 30.86 39.88 32.87
Depreciation 9.05 10.32 10.3 9.97 9.68
Exceptional Items 0 0 0 0 82.64
Profit Before Tax -7.03 62.4 -32.36 -24.99 64.67
Tax 0 0.38 -0.38 -0.14 0.21
Net Profit -7.03 62.02 -31.99 -24.85 64.46
Adjusted EPS (Rs.) -3.52 26.71 -13.49 -10.48 25.79

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 19.97 23.22 23.72 23.72 25
Total Reserves -183.03 -150.72 -182.74 -207.31 -142.83
Borrowings 230.92 153.73 99.01 123.03 99.54
Other N/C liabilities 20.45 6.19 6.78 7.33 8.2
Current liabilities 298.18 374.86 321.12 334.48 283.89
Total Liabilities 386.49 407.28 267.89 281.25 273.8
Assets
Net Block 180.27 186.34 178.33 172.36 163.9
Capital WIP 14.42 9.58 10.05 8.97 13.89
Intangible WIP 0 0 0 0 0
Investments 0.01 0.03 0.02 0.02 0.01
Loans & Advances 27.64 20.46 2.84 3.11 3.8
Other N/C Assets 0.26 0.43 0.41 0.07 0.1
Current Assets 163.89 190.45 76.23 96.72 92.11
Total Assets 386.49 407.28 267.89 281.25 273.8
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit from operations -7.03 62.4 -32.36 -24.99 64.67
Adjustment 47.85 -37.23 39.71 42.9 -41.41
Changes in Assets & Liabilities 2.36 18.26 26.04 11.88 20.9
Tax Paid -0.01 -0.04 -0.88 -0.06 -0.03
Operating Cash Flow 43.16 43.39 32.5 29.73 44.13
Investing Cash Flow -19.63 -13.06 -1.39 -3.07 63.66
Financing Cash Flow -28.07 -26.93 -33.26 -26.78 -107.87
Net Cash Flow -4.54 3.4 -2.15 -0.13 -0.09

Corporate Actions

Investors Details

PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Promoters 52.09 52.09 52.09 39.90 39.90
expert chemicals (... 40.00 40.00 40.00 30.64 30.64
kingsbury investme... 12.09 12.09 12.09 9.26 9.26
PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Investors 47.91 47.91 47.91 60.10 60.10
edelweiss asset re... 7.00 - - - -
edelweiss asset re... - 7.00 7.00 5.36 5.36
elizabeth mathew - - - 5.65 5.65
vijay k choraria - - - 2.83 2.83
bakliwal fincom pv... - - - 2.83 2.83
pandian ilangovan 2.00 1.94 1.94 1.47 1.47
suresh bhatia - - - 2.36 2.36
magnum equifin pri... 2.00 2.00 2.00 1.53 1.53
iepf 1.35 - 1.35 - -
investor education... - - - - -
east eight six adv... - - - 1.41 1.41
investor education... - 1.35 - 1.04 1.04
life insurance cor... 1.12 1.12 1.12 - -
milan manharkant g... - - - 1.18 1.18
general insurance ... - - - - -
varalakshmi veldi . - - 1.06 1.04 -
dipak kanayalal sh... - 1.05 1.06 - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Wanbury Stock Price Analysis and Quick Research Report. Is Wanbury an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Wanbury and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 44.127 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Wanbury has a Debt to Equity ratio of -1.3862 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Wanbury , the EPS growth was 346.179905709733 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Wanbury has OPM of -5.88314695661806 % which is a bad sign for profitability.
     
  • ROE: Wanbury have a poor ROE of 0 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Wanbury

X